Develops immune-oncology therapies to treat cancers through the inhibition of immune checkpoints.
Corvus Pharmaceuticals, Inc. is a dynamic clinical-stage biopharmaceutical company headquartered in Burlingame, California, dedicated to advancing cutting-edge immuno-oncology therapies. At the forefront of its innovative pipeline is Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody currently undergoing Phase Ib/II clinical trials for non-small cell lung cancer and head and neck cancers.
In addition to Mupadolimab, Corvus Pharmaceuticals is actively developing CPI-818, a covalent inhibitor of ITK, progressing through Phase I/Ib clinical trials targeting various malignant T-cell lymphomas. This novel therapy aims to disrupt the proliferation of specific malignant T-cells, potentially offering new treatment options for patients.
Furthermore, the company is advancing Ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor, currently in Phase II clinical trials for advanced or refractory renal cell cancer. Corvus Pharmaceuticals also maintains a robust portfolio of preclinical stage candidates, including CPI-182, an antibody designed to counteract inflammation and myeloid suppression, and CPI-935, an adenosine A2B receptor antagonist aimed at preventing fibrosis. With strategic collaborations such as its partnership with Angel Pharmaceuticals, Corvus Pharmaceuticals continues to accelerate the development of its targeted investigational medicines, striving to redefine treatment paradigms in oncology.